Abstract
Objective To evaluate the efficacy and safety of Paclitaxel drug coated balloon (DCB) (SeQuent Please©) in an elderly patients with de novo coronary disease. Methods We performed a retrospective study of 158 consecutive patients (63 patients aged ≥65 yrs and 95 patients aged <65 yrs) received DCB therapy in Cath Lab of Beijing Hospital. Clinical characteristic was recorded and coronary angiography was analyzed with quantitative coronary angiography(QCA) software. Results In elderly group, more patients have hypertension (65.1% vs. 56.8%), atrial fibrillation (7.9% vs. 2.1%), previous percutaneous coronary intervention (PCI) history (44.4% vs. 23.2%, P 0.05], the late lumen loss (LLL) was(-0.09±0.50) mm. At 9 months follow-up, the MACE rate in the elderly group was 1.6% and 1.1% in non-elderly group, with TLR rates at 0.0% and 1.1% respectively (both P>0.05). No death was observed in either group. Conclusions The efficacy and safety of DCB on the elderly patients with de novo lesions is as good as non-elderly patients despite more complex anatomy and comorbidities. Key words: Coronary diseases; Drug coated balloon; Treatment outcome
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
